$NVAX very long term promising outlook here but unfortunately there is an elephant in the room that is a common problem for many of these smaller biotechs. and that unfortunately is the need for capital. Before covid-19, I have had nvax on my watch list and have always noticed a pretty deep undertow of overhead. After digging in, you will see there is an astronomical part of the float that is being diluted to the tune of 20% of all shares outstanding per month. To substantiate this, look at the negative equity the company carries that falls in the range of a quarter billion dollars. Of course enough institutional buyers can always offset the undertow, however retail traders cannot. Could be a big rug pull soon following this euphoria or at least until hard study data gets revealed that what support higher institutional price targets.
  • 1
1 Like